Search results
Results from the WOW.Com Content Network
Dupilumab. Dupilumab, sold under the brand name Dupixent, is a monoclonal antibody blocking interleukin 4 and interleukin 13, used for allergic diseases such as atopic dermatitis (eczema), asthma and nasal polyps which result in chronic sinusitis. [6][7][8][4] It is also used for the treatment of eosinophilic esophagitis [9] and prurigo nodularis.
The UK's Medicines and Healthcare Regulatory Agency (MHRA) warned of some new and severe eye-related side effects following the use of Sanofi SA (NASDAQ: SNY) and Regeneron Pharmaceuticals Inc's ...
In 2022, a biologic drug called Dupixent (dupilumab) became the first FDA-approved treatment for PN. Previously, it was only approved for other skin conditions, such as atopic dermatitis. Studies ...
The most common side effects across indications include injection site reactions, conjunctivitis, conjunctivitis allergic, arthralgia, oral herpes and eosinophilia. Adverse events more commonly observed with Dupixent (≥5%) compared to placebo in either COPD trial were back pain, COVID-19, diarrhea, headache and nasopharyngitis.
Pupillary response is a physiological response that varies the size of the pupil, via the optic and oculomotor cranial nerve. A constriction response (miosis), [1] is the narrowing of the pupil, which may be caused by scleral buckles or drugs such as opiates / opioids or anti-hypertension medications. Constriction of the pupil occurs when the ...
Topical glucocorticoids are used in the treatment of many skin conditions. They provide anti-inflammatory, antimitotic, and immune-system suppressing actions through various mechanisms. [1] Hydrocortisone cream is a type of topical glucocorticoid that is commonly found on the market.
For premium support please call: 800-290-4726 more ways to reach us
About the Dupixent Pediatric Eosinophilic Esophagitis Trial The Phase 3 randomized, double-blind, placebo-controlled trial evaluated the efficacy and safety of Dupixent in children aged 1 to 11 years with EoE. Part A enrolled 102 patients and evaluated Dupixent at a weight-tiered higher dose or lower dose regimen, compared to placebo, for 16 weeks.